Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New model forecasts cancer recurrence risk in rectal patients

NCT ID NCT07351708

Knowledge-focused Sponsor: Cai Zerong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create a model that predicts whether rectal cancer will come back after treatment. Researchers looked at medical records and inflammation markers from over 2,300 patients with advanced rectal cancer who had chemotherapy or radiation before surgery. The goal was to help doctors identify patients at higher risk of local recurrence, so they can plan better follow-up care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,315 people

The number who actually took part.

Started

Jan 2010

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eight hundred and sixty-nine patients (median \[interquartile range\] age, 57 \[48, 64\] years; 70% \[611/869\] male) with LARC between January 2010 and December 2022 in SYSU6H served as the training cohort, while 1446 patients with LARC between January 2010 and December 2022 in CHH (median age, 62 \[54, 69\]; 62% \[902/1446\] male) were served as the validation cohort.

Ages

20 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed cT\>=3 or cN+ stage rectal cancer by pelvic MRI or enhanced CT scan; 2. Pathological proved primary rectal adenocarcinoma; 3. Recieved full-cource radiation or more than 3 cycles of chemotherapy before surgery; 4. Recieved radical tumor resection by TME surgery. Exclusion Criteria: 1. Diganosed with any distant metastasis disease or locally unresectable disease before neoadjuvant treatment or surgery; 2. Recieved local resection surgery (R2 resection) or postoperative pathology confirmed positive surgical margins (R1 resection); 3. Patients who died due to intra- or post-operative complications; 4. Patient who die or relapse within 30 days after surgery; 5. Patients who had a prior history of malignancy within 5 years before surgery; 6. Patients who were loss of follow-up or had inadequate clinical data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced rectal cancer (LARC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced rectal cancer (LARC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.